ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents AI-driven digital twin for simulation of aging eye
The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.
AnnMarie Hipsley, DPT, PhD, presented a transformative concept in ophthalmic innovation: the “digital twin” of the human eye, embodied in the Virtual Eye Simulation Analyzer (VESA)—a virtual, AI-driven model capable of simulating the anatomy and aging of the eye—at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California. A digital twin is a virtual representation of a physical entity, and in this case, VESA was developed over the past decade to model the full lifecycle of presbyopia.
Originally designed to explore treatment options from early to advanced stages of presbyopia, VESA creates a personalized 3D ID using topography, refractive data, and the material properties of ocular tissues. “It becomes a representation of a person’s eye,” Hipsley explained. In this study, a 52-year-old eye served as the baseline model, chosen for its biomechanical stability. Leveraging Ansys and proprietary physics-based modeling, VESA simulated changes in dioptric power, lens accommodation, and structural shifts in the sclera, lens, Bruch’s membrane, and zonular fibers.
VESA’s next step: simulation of personalized treatments tailored to specific ages and anatomical profiles. “VESA was able to calculate and spit out precision patterns for each of those stages and ages,” Hipsley said. The system’s predictive capacity opens doors to virtual IOL implantation and treatment planning, allowing innovators to “test your innovation virtually… and come up with fail-fast answers” before entering clinical trials.
With patient data stored securely on a 3D ID card, the system supports longitudinal care and privacy. “Every single patient becomes 1000 simulations of data,” Hipsley noted, positioning VESA as a future-forward tool for real-time clinical updates, predictive diagnostics, and a major step toward individualized, minimally invasive ophthalmic care.
Explore More Articles
Is Presbyopia Finally Taking Center Stage?
Presbyopia is the eye condition that will impact 100% of patients at some point. It has long been said that a solution for presbyopia is the “holy grail” of eye care. While there is not yet a cure for presbyopia, there are more tools than ever before to help patients have functional near and intermediate …
read morePathogenesis of Presbyopia: A New Understanding of an Age-Old Disease
FOR MOST OF HISTORY, PRESBYOPIA has been defined as a “normal” refractive error caused by age, with discussion limited to the loss of near vision beginning in our 40s. Because we have had no effective therapeutic interventions available, presbyopia has been accepted as a natural part of life and treated primarily by changing power at either …
read moreVIDEO: New laser offers further improvement to laser scleral microporation
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, AnnMarie Hipsley, DPT, PhD, and George O. Waring IV, MD, FACS, discuss the latest advances in laser scleral microporation.Hipsley said that the GenII VisioLite laser for laser scleral microporation (LSM) is on the pathway to commercialization and may be available by the end of the year.
read more